NDA 213969 · Sentynl Theraps INC
Zokinvy
Lonafarnib · Oral · Farnesyltransferase Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Nov 20, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
37
4 Phase 3, 0 recruiting
FAERS reports
78
42 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 2, 2025.
ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m 2 and above: To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) For the treatment of processing-deficient Progeroid Laminopathies with either: Heterozygous LMNA mutation with progerin-like protein accumulation Homozygous or compound heterozygous ZMPSTE24 mutations ZOKINVY is a farnesyltransferase inhibitor indicated in patients 12 months of age and older with a body surface area of 0.39 m 2 and above: ( 1 ) To reduce risk of mortality in Hutchinson-Gilford Progeria Syndrome. For treatment of processing-deficient Progeroid Laminopathies with either: Heterozygous LMNA mutation with progerin-like protein accumulation. Homozygous or compound heterozygous ZMPSTE24 mutations. Limitations of Use Not indicated for other Progeroid Syndromes or processing-proficient Progeroid Laminopathies. Based upon its mechanism of action, ZOKINVY would not be expected to be effective in these populations. ( 1 ) Limitations of Use ZOKINVY is not indicated for other Progeroid Syndromes or processing-proficient Progeroid Laminopathies. Based upon its mechanism of action, ZOKINVY would not be expected to be effective in these populations.
Mechanism: Lonafarnib inhibits farnesyltransferase to prevent farnesylation and subsequent accumulation of progerin and progerin-like proteins in the inner nuclear membrane.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 20, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelReviewLetter
2 products under this application
- ZOKINVY · LONAFARNIB 75MG · CAPSULE, ORAL · Prescription
- ZOKINVY · LONAFARNIB 50MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lonafarnib" as an intervention, any sponsor and status, largest first.
- Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00050336 · 702 participants · Start Dec 2002 · Primary completion Feb 2004
Drug: Lonafarnib (SARASAR) · For: Carcinoma, Non-small-cell Lung; Metastases, Neoplasm
- Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2aPivotal-lookingCompleted
Eiger BioPharmaceuticalsIndustry
NCT03719313 · 407 participants · Start Dec 1, 2018 · Primary completion Oct 6, 2022
Drug: Lonafarnib; Ritonavir and 3 more · For: Hepatitis Delta Virus
Sites: Fresno, California; Los Angeles, California; Palo Alto, California · 116 sites in all
- Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00081510 · 110 participants · Start Dec 2003 · Primary completion May 2009
Drug: Lonafarnib; Placebo and 1 more · For: Breast Cancer
- Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian CancerPivotal-lookingCompleted
AGO Study GroupAcademic, hospital or other
NCT00281515 · 105 participants · Start Jan 2006 · Primary completion Dec 2011
Drug: Lonafarnib · For: Epithelial Ovarian Cancer
Sites: Berlin, Germany; Bremen, Germany; Dresden, Germany · 23 sites in all
Boston Children's HospitalAcademic, hospital or other
NCT00916747 · 85 participants · Start Aug 2009 · Primary completion Feb 2022
Drug: Lonafarnib, Zoledronic Acid, and Pravastatin · For: Progeria
Sites: Boston, Massachusetts
- Phase I/II Trial of Everolimus in Combination With Lonafarnib in ProgeriaEnrolling by invitation
Boston Children's HospitalAcademic, hospital or other
NCT02579044 · 80 participants (planned) · Start Dec 2015 · Primary completion Mar 2027
Drug: Everolimus and lonafarnib · For: Progeria
Sites: Boston, Massachusetts
- Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)Completed
EIT Pharma, Inc.Industry
NCT02430194 · 55 participants · Start Dec 2014 · Primary completion Apr 18, 2017
Drug: lonafarnib; ritonavir and 1 more · For: Chronic Hepatitis D Infection
Sites: Ankara, Turkey (Türkiye)
Pediatric Brain Tumor ConsortiumResearch network
NCT00015899 · 53 participants · Start Jan 2002 · Primary completion Sep 2005
Drug: lonafarnib · For: Brain and Central Nervous System Tumors
Sites: San Francisco, California; Washington D.C., District of Columbia; Boston, Massachusetts · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue23
- diarrhoea16
- vomiting12
- death4
- headache4
- abdominal pain upper3
- asthenia3
- cardiac operation3
- fatigue3
- malaise3
- nausea3
- product supply issue3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 21 |
| 2022 | 15 |
| 2023 | 9 |
| 2024 | 7 |
| 2025 | 2 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
Yurdaydin C, Keskin O, Kalkan Ç, et al. · Hepatology 2018 · Clinical Trial, Phase II
- Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.
Buresh A, Perentesis J, Rimsza L, et al. · Leukemia 2005 · Clinical Trial, Letter
- Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
Milojkovic Kerklaan B, Diéras V, Le Tourneau C, et al. · Cancer Chemother Pharmacol 2013 · Clinical Trial, Phase I, Multicenter Study
- Comparative Efficacy of Treatment Regimens for Chronic Hepatitis D Virus Infection: A Systematic Review and Network Meta-Analysis.
Ouranos K, Mylona EK, Dellis C, et al. · Liver Int 2025 · Systematic Review, Comparative Study
- Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
Yust-Katz S, Liu D, Yuan Y, et al. · Cancer 2013 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Sentynl Theraps INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.